Changes in the proteomic profile of blood serum in coronary atherosclerosis and abdominal obesity

Background – to study the relationship of blood proteins with abdominal obesity in patients with coronary atherosclerosis by quantitative proteomic analysis. Methods. The study involved patients with coronary atherosclerosis (n = 36), with an average age of 57 ± 7 years. The research material is blood serum. Protein concentrations in serum samples were determined using the PeptiQuant Plus Proteomics Kit. The identification of protein fractions was carried out by monitoring multiple reactions on a Q-TRAP 6500 mass spectrometer combined with a liquid chromatograph. Results. Mass spectrometric identification revealed lower concentrations of proteins in blood serum samples from patients with coronary atherosclerosis and abdominal obesity: serum albumin, apolipoproteins A (I, IV), C (I, III, IV), L1, thrombospondin 1, PAI 1, coagulation factors (X, XII), complement factor H, fibronectin, CD5 antigenlike protein, phospholipid-transferring protein, gelsolin and osteonectin, compared with those without AO. The differences were considered significant at p < 0.05. In patients with coronary atherosclerosis, a correlation was found between AO and osteonectin (r = –0.603; p = 0.0001). In addition, the presence of AO is associated with the concentration of osteonectin (B = –0,087; Exp(B) = 0,916; ДИ 0,843– 0,996; p = 0,039) and gelsolin (B = –0,092; Exp(B) = 0,912; ДИ 0,839–0,991; p = 0,029). Conclusions. In this study, we found a decrease in blood concentrations of proteins associated with the inflammatory process, lipid metabolism, adaptive immune responses in coronary atherosclerosis and AO. In addition, in coronary atherosclerosis, the reverse association of AO with gelzolin and osteonectin, a well-known marker of arterial calcification, was revealed. These results can serve as a basis for further research, as well as for a better understanding of the effect of AO on coronary atherosclerosis.

1. Carbone S., Canada J.M., Billingsley H.E., Siddiqui M.S., Elagizi A., Lavie C.J. Obesity paradox in cardiovascular disease: where do we stand? Vasc. Health Risk Manag. 2019; 15: 89–100. doi: 10.2147/VHRM.S168946

2. Garbuzova E.V., Polonskaya Ya.V., Kashtanova E.V., Stakhneva E.M., Shramko V.S., Murashov I.S., Kurguzov A.V., Chernyavsky A.M., Ragino Yu.I. Adipokines in atherosclerotic plaques in men with coronary atherosclerosis. Cardiology. 2024; 64 (8): 39–47. doi: 10.18087/cardio.2024.8.n2634 (In Russ.)

3. Yuxiang L., Fujiu K. Human Resistin and Cardiovascular Disease. Int. Heart J. 2020; 61 (3): 421–423. doi: 10.1536/ihj.20-221

4. Francisco V., Pino J., Gonzalez-Gay M.A., Mera A., Lago F., Gómez R., Mobasheri A, Gualillo O. Adipokines and inflammation: is it a question of weight? Br. J. Pharmacol. 2018; 175 (10): 1569–1579. doi: 10.1111/bph.14181

5. Ledovskikh S.R., Garbuzova E.V., Shramko V.S., Kashtanova E.V., Polonskaya Ya.V., Stakhneva E.M., Kurguzov A.V., Chernyavsky A.M., Ragino Yu.I. Molecules secreted by visceral adipocytes in patients with coronary atherosclerosis and insulin resistance. Russ. J. Cardiol. 2024; 29 (8): 5788. doi: 10.15829/15604071-2024-5788 (In Russ.)

6. Powell-Wiley T.M., Poirier P., Burke L.E., Des prés J.P., Gordon-Larsen P., Lavie C.J., Lear S.A., Ndumele C.E., Neeland I.J., Sanders P., St-Onge M.P. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021; 143 (21): e984–e1010. doi: 10.1161/CIR.0000000000000973

7. Liu Q., Cui H., Si F., Wu Y., Yu J. Association of Cumulative Exposure to Metabolic Score for Visceral Fat With the Risk of Cardiovascular Disease and All-Cause Mortality: A Prospective Cohort Study. J. Cachexia Sarcopenia Muscle. 2025; 16 (1): e13702. doi: 10.1002/jcsm.13702

8. Kang M.K., Song J.E., Kweon Y.O., Tak W.Y., Park S.Y., Lee Y.R., Park J.G. Visceral Obesity and Its Association with Severe Coronary Artery Calcification in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease. Diagnostics (Basel). 2024; 14 (20): 2305. doi: 10.3390/diagnostics14202305

9. Striukova E.V., Shramko V.S., Kashtanova E.V., Polonskaya Y.V., Stakhneva E.M., Kurguzov A.V., Chernyavsky A.M., Ragino Y.I. Adipokine Levels in Men with Coronary Atherosclerosis on the Background of Abdominal Obesity. J. Pers. Med. 2022; 12 (8): 1248. doi: 10.3390/jpm12081248

10. Després J.P. What is «metabolically healthy obesity»? From epidemiology to pathophysiological insights. J. Clin. Endocrinol. Metab. 2012; 97: 2283–2285. doi: 10.1210/jc.2012-2081

11. Camhi S.M., Must A., Gona P.N., Hankinson A., Odegaard A., Reis J., Gunderson E.P., Jacobs D.R., Carnethon M.R. Duration and stability of metabolically healthy obesity over 30 years. Int. J. Obes. (Lond.). 2019; 43: 1803–1810. doi: 10.1038/s41366-018-0197-8

12. Stakhneva E.M., Meshcheryakova I.A., Demidov E.A., Starostin K.V., Sadovski E.V., Peltek S.E., Voevoda M.I., Chernyavskii A.M., Volkov A.M., Ragino Yu.I. A Proteomic Study of Atherosclerotic Plaques in Men with Coronary Atherosclerosis. Diagnostics. 2019. 9 (4): E177. doi: 10.3390/diagnostics9040177

13. Yuan S., Burgess S., Laffan M., Mason A.M., Dichgans M., Gill D., Larsson S.C. Genetically Proxied Inhibition of Coagulation Factors and Risk of Cardiovascular Disease: A Mendelian Randomization Study. J. Am. Heart Assoc. 2021;10 (8): e019644. doi: 10.1161/JAHA.120.019644

14. Vasiliev S.A., Gorgidze L.A., Efremov E.E., Belinin G.Yu., Moiseeva T.N., Al-Radi L.S., Sokolova M.A., Guria G.T., Zozulya N.I., Kokhno A.V. Fibronectin: structure, functions, clinical significance (review). Atherothrombosis. 2022; 12 (1): 138–158. doi: 10.21518/2307-1109-2022-12-1-138-158 (In Russ.)

15. Badimon L., Vilahur G. Thrombosis formation on atherosclerotic lesions and plaque rupture. J. Intern. Med. 2014; 276 (6): 618–632. doi: 10.1111/joim.12296

16. Ragino Y.I., Striukova E.V., Murashov I.S., Polonskaya Y.V., Volkov A.M., Kurguzov A.V., Chernjavskii A.M., Kashtanova E.V. Association of some hemostasis and endothelial dysfunction factors with probability of presence of vulnerable atherosclerotic plaques in patients with coronary atherosclerosis. BMC Res. Notes. 2019; 12 (1): 336. doi: 10.1186/s13104-019-4360-7

17. Kamma E., Becquart P., Traboulsee A., Schabas A., Vava sour I.M., Laule C., Vilariño-Güell C., Quandt J.A. Elevated levels of serum CD5 antigen-like protein distinguish secondary progressive multiple sclerosis from other disease subtypes. Mult. Scler. Relat. Disord. 2021; 56: 103269. doi: 10.1016/j.msard.2021.103269

18. Jiang X.C., Yu Y. The Role of Phospholipid Transfer Protein in the Development of Atherosclerosis. Curr. Atheroscler. Rep. 2021; 23 (3): 9. doi: 10.1007/s11883-021-00907-6

19. Mukherjee R., Yun J.W. Long chain acyl CoA synthetase 1 and gelsolin are oppositely regulated in adipogenesis and lipogenesis. Biochem. Biophys. Res. Commun. 2012; 420 (3): 588–593. doi: 10.1016/j.bbrc.2012.03.038

20. Al-Domi H.A., Al Haj Ahmad R.M. Association between complement component C3 and body composition: a possible obesity inflammatory biomarker for insulin resistance. Asia Pac. J. Clin. Nutr. 2017; 26 (6): 1082–1087. doi: 10.6133/apjcn.012017.02

21. Stakhneva E.M., Kashtanova E.V., Polonskaya Ya.V., Garbuzova E.V., Shramko V.S., Sadovsky E.V., Kurguzov A.V., Murashov I.S., Chernyav sky A.M., Ragino Yu.I. Association of acute phase proteins in the blood with the presence of unstable atherosclerotic plaques in coronary atherosclerosis. Prof. Med. 2023, 26 (8): 76–81. doi: 10.17116/profmed20232608176 (In Russ.)

22. Rosset E.M., Bradshaw A.D. SPARC/osteonectin in mineralized tissue. Matrix Biol. 2016; 52-54: 78–87. doi: 10.1016/j.matbio.2016.02.001

23. Ryu S., Sidorov S., Ravussin E., Artyomov M., Iwasaki A., Wang A., Dixit V.D. The matricellular protein SPARC induces inflammatory interferon-response in macrophages during aging. Immunity. 2022; 55 (9): 1609–1626.e7. doi: 10.1016/j.immuni.2022.07.007

24. Toba H., de Castro Brás L.E., Baicu C.F., Zile M.R., Lind sey M.L., Bradshaw A.D. Secreted protein acidic and rich in cysteine facilitates age-related cardiac inflammation and macrophage M1 polarization. Am. J. Physiol. Cell Physiol. 2015; 308 (12): 972–982. doi: 10.1152/ajpcell.00402.2014